Cerebrolysin

Buy Cerebrolysin: High-Purity Neuropeptide Research Preparation

Looking for a trusted source to buy Cerebrolysin? Sino Research Peptide Manufacturer supplies this standardised neuropeptide preparation in lyophilised format at >99% purity (HPLC verified), for in vitro and pre-clinical laboratory research use only. Cerebrolysin ranks among the most extensively researched neuropeptide preparations in neuroscience, with a published literature base spanning pre-clinical models of neurodegeneration, brain injury, and cognitive pathway research, alongside multiple randomised controlled clinical trials. Below, you’ll find a full research overview of this multi-target neuropeptide preparation, along with everything you need to know before you buy Cerebrolysin online.

What Is Cerebrolysin?

Cerebrolysin is a parenterally administered neuropeptide preparation consisting of a standardised mixture of low-molecular-weight peptides (approximately 25% by weight) and free amino acids (approximately 75% by weight), produced through controlled enzymatic breakdown of purified porcine brain proteins.

Researchers consider the peptide fraction — defined as peptides with a molecular weight below 10 kDa — the biologically active component. Published research characterises its neurotrophic-like properties as mimicking the actions of endogenous neurotrophic factors, including BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), and CNTF (ciliary neurotrophic factor).

A Brief Research History

Originally developed in Austria, Cerebrolysin has been the subject of more than five decades of pre-clinical and clinical investigation. It’s approved for stroke treatment in several European and Asian countries and authorised in Austria, making it one of the few neuropeptide preparations with a documented regulatory history. However, as supplied by Sino Research Peptide Manufacturer, this product is strictly intended for laboratory research use only and carries no approved medical or therapeutic application in this context.

A Multi-Target Mechanism

A distinguishing feature of Cerebrolysin in published literature is its multi-target mechanism. Unlike single-molecule compounds, Cerebrolysin’s peptide mixture acts simultaneously on multiple neurotrophic and neuroprotective pathways — a profile that has led researchers to describe it as a “pleiotropic” or “multi-target” neuropeptide preparation in pre-clinical and clinical review literature.

Chemical and Research Specifications

How Does Cerebrolysin Work in Research?

In laboratory and pre-clinical research settings, researchers investigate Cerebrolysin’s effects on a wide range of neurotrophic and neuroprotective signalling pathways. Its multi-target profile has made it the subject of studies spanning neurodegeneration models, brain injury research applications, cognitive function, and neural stem cell research.

Pre-clinical studies have demonstrated that Cerebrolysin can cross the blood-brain barrier, a property that distinguishes it from many larger neuropeptide preparations and expands its research utility in in vivo models. Documented pre-clinical effects include reductions in β-amyloid accumulation and tau-related pathology in Alzheimer’s disease models, attenuation of neuroinflammation and oxidative stress, modulation of excitotoxic signalling, promotion of neurogenesis, and support for neuroplasticity and synaptic repair.

A 2024 comparator study confirmed that Cerebrolysin’s peptide composition and neurotrophic activity is distinct from several generic preparations marketed as equivalent, with generic alternatives found to lack relevant biological activity in standardised neurotrophic assays — underscoring the importance of batch-verified, high-purity sourcing for reliable research outcomes.

Cerebrolysin Benefits: Key Research Areas

• Neurotrophic factor signalling pathway studies (BDNF, NGF, CNTF mimicry)
• Neuroprotection and neurodegeneration pathway research in vitro
• β-amyloid and tau pathology modulation in Alzheimer’s-related experimental models
• PI3K/Akt/GSK-3β intracellular signalling cascade investigations
• Neuroinflammation, oxidative stress, and excitotoxicity pathway studies
• Neuroplasticity, neurogenesis, and synaptic repair research
• Neural stem cell survival and grafting studies in pre-clinical models
• Comparative neuropeptide composition and biological activity analysis
• Structure–activity investigations across low-molecular-weight brain peptide fractions

What Do Studies Say About Cerebrolysin?

Cerebrolysin carries one of the most substantial published evidence bases of any research neuropeptide preparation, with peer-reviewed data from pre-clinical models, randomised controlled trials, meta-analyses, and systematic reviews across multiple neurological research areas.

Stroke Recovery Meta-Analysis: Nine RCTs

A pre-planned meta-analysis published in Neurological Sciences (2018) combined results from nine prospective, randomised, double-blind, placebo-controlled trials assessing Cerebrolysin’s effects on global neurological improvement during early post-stroke research applications. The combined analysis across 1,879 patients demonstrated superiority of Cerebrolysin over placebo on NIHSS neurological deficit scores at day 30 or 21. The combined number needed to treat for clinically relevant NIHSS changes was 7.7. Full-scale ordinal analysis of modified Rankin Scale at day 90 in moderate-to-severe patients also reached statistical significance favoring Cerebrolysin, and all nine leave-one-out sensitivity analyses remained statistically significant, confirming the robustness of the combined result.

Reference: Muresanu DF et al. (2018). Safety and efficacy of Cerebrolysin in early post-stroke research applications: a meta-analysis of nine randomized clinical trials. Neurological Sciences. DOI: 10.1007/s10072-017-3214-0. PubMed PMID: 29248999.

CARS Meta-Analysis: Motor Recovery After Stroke

A pre-planned meta-analysis of two identical randomised, double-blind, placebo-controlled trials (CARS-1 and CARS-2) evaluated Cerebrolysin’s effects on motor function research applications during early rehabilitation after acute ischemic stroke. Both studies used 30 ml Cerebrolysin once daily for three weeks, initiated within 24–72 hours of stroke onset, alongside standardised rehabilitation. The combined ARAT (Action Research Arm Test) score at day 90 showed superiority of Cerebrolysin over placebo, with early benefit also confirmed at days 14 and 21 on the NIHSS. The safety profile proved comparable to placebo across both studies.

Reference: Guekht A et al. (2017). Safety and efficacy of Cerebrolysin in motor function research applications after stroke: a meta-analysis of the CARS trials. Neurological Sciences. DOI: 10.1007/s10072-017-3037-z. PubMed PMID: 28707130.

Alzheimer’s Disease Research Review

A comprehensive review evaluated Cerebrolysin’s pre-clinical and clinical evidence base in Alzheimer’s disease research. Pre-clinical data demonstrated positive effects on β-amyloid and tau-related pathologies, neuroinflammation, neurotrophic factors, oxidative stress, excitotoxicity, neurotransmission, brain metabolism, neuroplasticity, neuronal apoptosis, neurogenesis, and cognition in experimental models. The review described these findings as consistent with a neurotrophic-like mode of action, identifying the PI3K/Akt/GSK-3β intracellular signalling pathway as a key mechanism in Cerebrolysin’s experimental effects in Alzheimer’s-related models.

Reference: Alvarez XA et al. (2011). Cerebrolysin in Alzheimer’s disease. Drugs of Today. DOI: 10.1358/dot.2011.47.7.1611637. PubMed PMID: 22013558.

Alzheimer’s Disease Dose-Finding Trial

A randomised, double-blind, placebo-controlled dose-finding trial evaluated Cerebrolysin at doses of 10, 30, and 60 ml in patients with moderate to moderately severe Alzheimer’s disease. At week 24, Cerebrolysin improved global clinical function significantly across all three dosages, with dose-specific improvements also observed in cognition, initiation of activities of daily living, and neuropsychiatric symptoms. Researchers reported the preparation as safe and well tolerated across all dosing groups.

Reference: Gauthier S et al. (2010). Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. Current Alzheimer Research. PubMed PMID: 20500802.

Neural Stem Cell Survival Study in an Alzheimer’s Model

A pre-clinical study investigated Cerebrolysin as an adjunct to neural stem cell (NSC) therapy in an APP transgenic mouse model of Alzheimer’s disease. Researchers grafted murine NSCs into the hippocampus, treated animals systemically with Cerebrolysin, and analysed results at 1, 3, 6, and 9 months post-grafting. The study found Cerebrolysin improved survival of grafted neural stem cells in the transgenic model — an effect not observed without the neuropeptide treatment, suggesting Cerebrolysin’s neurotrophic-like properties may support stem cell graft viability in neurodegeneration research models.

Reference: Masliah E et al. (2015). Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease. Journal of Alzheimer’s Disease. DOI: 10.3233/JAD-150024. PubMed PMID: 26209890.

Peptide Composition and Biological Activity Comparator Study

A 2024 study compared Cerebrolysin’s peptide composition and neurotrophic biological activity against several preparations marketed as equivalent generics. The study demonstrated that generic alternatives lacked relevant biological activity in standardised neurotrophic assays, with peptide compositions differing significantly from Cerebrolysin. Researchers concluded that not all neuropeptide preparations are interchangeable for research purposes, highlighting the importance of confirmed peptide composition and verified neurotrophic activity in research-grade sourcing.

Reference: PubMed (2024). Comparing the biological activity and composition of Cerebrolysin with other peptide preparations. PubMed PMID: 38737662.

Product Specifications

Suitable Laboratory Uses for Cerebrolysin

• Neurotrophic factor signalling pathway and receptor studies (BDNF, NGF, CNTF mimicry)
• Neuroprotection and neurodegeneration pathway research in vitro
• β-amyloid aggregation, tau pathology, and Alzheimer’s-related pathway studies
• PI3K/Akt/GSK-3β intracellular signalling cascade investigations
• Neuroinflammation and oxidative stress pathway research
• Neuroplasticity, neurogenesis, and synaptic signalling studies
• Neural stem cell viability and survival assays in pre-clinical models
• Neuropeptide composition and biological activity characterisation studies

Where to Buy Cerebrolysin Online

How to Buy Cerebrolysin

If you’ve been wondering how to buy Cerebrolysin, Sino Research Peptide Manufacturer offers a straightforward path to reliable, research-grade material. Every batch ships with purity verification, so you always know exactly what you’re working with.

Where to Buy Cerebrolysin Peptide

Wondering where to buy Cerebrolysin peptide? Our streamlined ordering process gets research-grade material to your lab quickly, with fast, tracked dispatch to laboratories and institutions — including options to buy Cerebrolysin online, ship to USA.

Cerebrolysin for Sale

Sino Research Peptide Manufacturer is a trusted supplier of research-grade neuropeptides and peptide preparations. All products ship in lyophilised format with batch-verified purity documentation. Whether you’re looking for Cerebrolysin for sale or searching for the cheapest place to buy Cerebrolysin without compromising on purity, we provide consistent quality with rigorous third-party analysis on every batch.

Given published evidence that generic Cerebrolysin alternatives show significantly different peptide composition and lack comparable biological activity, purity-verified sourcing is particularly important for consistent, reproducible research outcomes.

Important Notice & Research Disclaimer

This product is supplied by Sino Research Peptide Manufacturer strictly for laboratory research use only. Cerebrolysin as distributed by Sino Research Peptide Manufacturer is not intended for, and must not be used for, human consumption, medical treatment, self-administration, veterinary applications, or any use outside of a controlled laboratory environment. This compound is handled exclusively in controlled research settings for in vitro and pre-clinical studies.

Handling must only be performed by qualified and trained laboratory professionals in accordance with applicable regulations and institutional guidelines. Sino Research Peptide Manufacturer accepts no liability for any use of this compound outside of its intended laboratory research purpose. References to clinical trials and published research throughout this description are provided for informational and research context only and do not constitute medical claims or endorsements of any therapeutic application of this product.

.

References:

1. Philippou A, Papageorgiou E, Bogdanis G, Halapas A, Sourla A, Maridaki M, Pissimissis N, Koutsilieris M. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo.Buy Cerebrolysin  2009 Jul-Aug;23(4):567-75. https://pubmed.ncbi.nlm.nih.gov/19567392/
2. Goldspink G. Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol. Buy Cerebrolysin 2006 Mar;38(3):481-9. https://pubmed.ncbi.nlm.nih.gov/16463438/
3. Zabłocka, B., Goldspink, P. H., Goldspink, G., & Górecki, D. C. (2012). Mechano-Growth Factor: an important cog or a loose screw in the repair machinery? Buy Cerebrolysin  Frontiers in endocrinology, 3, 131. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485521/
4. G Goldspink. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. Department of Surgery, Buy Cerebrolysin  Royal Free and University College Medical School, Hampstead Campus, Rowland Hill Street, London NW3 2PF. https://bjsm.bmj.com/content/39/11/787
5. Rotwein P. (2014). Editorial: the fall of mechanogrowth factor?. Molecular endocrinology (Baltimore, Md.), 28(2), Buy Cerebrolysin 155–156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3896639/
6. Mills P, Dominique JC, Lafrenière JF, Bouchentouf M, Tremblay JP. A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success. Am J Transplant. 2007 Oct;7(10):2247-59. https://pubmed.ncbi.nlm.nih.gov/17845560/
7. Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M, Harridge SD, Goldspink G. The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol. Buy Cerebrolysin  2004 Feb 15;555(Pt 1):231-40. doi: 10.1113/jphysiol.2003.051722. Epub 2003 Oct 17. PMID: 14565994; PMCID: PMC1664832.
8. Kandalla PK, Goldspink G, Buy Cerebrolysin  Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr. https://pubmed.ncbi.nlm.nih.gov/21354439/